Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03646123 : Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

12+Age Over 12

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma)

Trial Overview Read MoreRead more

This Phase II trial is evaluating how effective two different combinations of treatments including anticancer drugs, chemotherapy and immunotherapy, are at treating classical Hodgkin lymphoma.
 

This trial is treating patients with Hodgkin's Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Commercial Sponsor

Seagen Inc.

Summary

This is a non-randomised, parallel assignment study that has three parts. Part A involves the anticancer drug Brentuximab vedotin and chemotherapy drugs doxorubicin, vinblastine, and dacarbazine (this combination is also known as A+AVD) being administered separately via intravenous infusion (IV) to participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle. Participants in Part A will also be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Part B involves the anticancer drug Brentuximab vedotin, immunotherapy drug nivolumab, and chemotherapy drugs doxorubicin and dacarbazine (this combination is also known as AN+AD) being administered separately via IV to participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle. Part C involves AN+AD being administered separately via IV in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.

Recruiting Hospitals Read MoreRead more

Ballarat Hospital
Ballarat
Ms Carmel Goss
CarmelG@bhs.org.au
03 5320 4735

Epworth Hospital Haematology
East Melbourne
Dr Connie Barlas
connie.barlas@epworth.org.au
03 9516 2374

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next